ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,164.05
0.13%
Dow Jones
39,958.97
0.26%
Gold vs US Dollar
2,363.955
-1.86%
Brent Oil
80.355
-0.47%
Bitcoin
64,805.54
-0.86%
Pepperstone
Advertisement
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. AMEX

  6. Actinium Pharmaceuticals Inc (ATNM) Share Price

ATNM Actinium Pharmaceuticals Inc

7.97
0.23 (2.97%)
Last Updated: 15:37:57
Delayed by 15 minutes
 Name  Symbol  Market  Type  ISIN  Description 
 Actinium Pharmaceuticals Inc AMEX:ATNM American Stock Exchange Common Stock  Common Stock Delaware
     Change  % Chg  Cur  Bid  Offer  High  Low  Open  Volume  Chg Time
Upgrade Icon
 		 RN  NRN 
   0.23 2.97 7.97 0.00 0.00 8.08 7.7501 7.89 87,953 14:37:57   
*quotes are delayed by at least 20 minutes
 Sector  Turnover  Profit  EPS - Basic  PE ratio  Mkt Cap 
 Pharmaceutical Preparations 81k -48.82M -1.6391 -4.88 230.52M
 Type  Size  Price  Time  Units 
 9 60 7.9391 14:37:57 USD
 
Pre-Market and After-Hours
Recent News
DateTimeSource
HeadlineMore ATNM News
25/07/202413:45PRNUSActinium Announces FDA Clearance of Iomab-ACT Targeted Conditioning IND Application for Sickle Cell Disease Patients Undergoing Bone Marrow Transplant in Collaboration with Columbia University
25/07/202412:30PRNUSActinium Pharmaceuticals to Present at the 3rd Annual Targeted Radiopharmaceuticals Summit US
17/06/202413:00PRNUSActinium Presents First Ever Data Demonstrating Actimab-A in Combination with Leading Menin Inhibitors Leads to Anti-Tumor Control and Potent Leukemic Cell Killing in Preclinical Acute Myeloid Leukemia Models at the 2024 EHA Congress
14/06/202413:30PRNUSActinium Highlights Oral Presentation at EHA 2024 Annual Congress Featuring Improved Outcomes in TP53 Positive Patients Receiving Iomab-B in the Phase 3 SIERRA Trial
11/06/202413:30PRNUSActinium Announces Results of Actimab-A + CLAG-M Combination Trial Highlighted in Oral Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting
10/06/202413:30PRNUSActinium Highlights Mutation Data from the Phase 3 SIERRA Trial of Iomab-B and Novel Linker Technology to Support Solid Tumor Antibody Radiation Conjugate Development at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting
15/05/202413:30PRNUSActinium to Host KOL Webinar to Discuss Iomab-ACT Commercial CAR T-Cell Therapy Trial Design, Objectives and Potential Market Opportunity
Period
Draw mode
Data Downloads for ATNM

Export historical price information open, high, low, close, volume (OHLCV) to Excel

Intraday price data (2 weeks, 1 minute bars)


Loading Follow Feed...

Latest Actinium Pharmaceuticals Inc Articles